Diclofenac 150 mg was superior to placebo for 4 of 5 primary efficacy measures ( all but swollen joint count ; p < 0.05 ) and meloxicam 15 mg was superior for 3 of 5 primary endpoints ( patient pain and patient and physician global ) .
